samedan logo

 
 
spacer
home > ebr > autumn 2017 > driving discovery
PUBLICATIONS
European Biopharmaceutical Review

Driving Discovery

Cytochromes P450 (P450s) are a superfamily of enzymes present in all organisms. They contain a haem moiety that forms the catalytic centre and primarily function as monooxygenases, adding an oxygen to their substrates (see Figure 1) (1). P450s are highly relevant in drug discovery because they are responsible for Phase 1 metabolism of approximately 70-80% of drugs (2). Several P450 isoforms contribute to human drug metabolism; the most important of these are summarised in Figure 2. Many issues affecting potential drugs can arise from P450 metabolism:

  • Rapid metabolism can lead to poor bioavailability or rapid clearance, resulting in low exposure and efficacy
  • Co-administration of drugs can cause drug-drug interactions (DDIs), whereby inhibition or induction of a P450 isoform by one therapeutic can dramatically affect the metabolism of another, causing significant changes in exposure
  • Genetic polymorphisms in patient populations affect the rates of metabolism by major P450 isoforms, including CYP2D6 and CYP2C19, generating large variabilities in exposure between patients
  • Metabolism by P450s can lead to bioactivation of compounds and the formation of reactive or toxic metabolites

In an effort to reduce these issues, in vitro assays of P450 metabolism-related properties are widely used in the drug discovery process (3). High-throughput assays, such as measurement of turnover in human liver microsomes or inhibition of P450 isoforms, are applied as early screens. However, more detailed studies, such as metabolite identification, remain expensive and time-consuming, hence they are typically applied later in the process to a limited number of compounds.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthew Segall has an MSc in computation from the University of Oxford, UK, and a PhD in theoretical physics from the University of Cambridge, UK. At Camitro, ArQule and Inpharmatica, he led a team developing predictive absorption, distribution, metabolism and excretion (ADME) models and intuitive decision-support tools for drug discovery. In 2006, Matt became responsible for management of Inpharmatica's ADME business and, following acquisition of Inpharmatica, he took up the role of Senior Director of BioFocus DPI's ADMET division. In 2009, he led a management buyout of the StarDrop business to found Optibrium Ltd, which develops software for small molecule design, optimisation and data analysis.
spacer
Matthew Segall
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Rousselot® Biomedical Announces the Launch of Quali-Pure HGP 2000

Irving, United States, May 4 2022 / Sciad Newswire / Rousselot®, Darling Ingredients’ health brand and the global leader of collagen-based solutions1, launches Quali-Pure™ HGP 2000, a new endotoxin-controlled, pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications. As the latest addition to Rousselot Biomedical’s rapidly expanding product offering, this new non-gelling hydrolyzed gelatin further extends the scope of biomedical applications covered by Rousselot products.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement